The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Peptide ELISA: antibody detection limit dilution 1:16,000.
WB: Use at a concentration of 0.5 - 1.5 µg/ml. Detects a band of approximately 69 kDa (predicted molecular weight: 69 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle.
Major sites of expression are liver, kidney and adipocytes.
Carbohydrate biosynthesis; gluconeogenesis.
Involvement in disease
Defects in PCK1 are the cause of cytosolic phosphoenolpyruvate carboxykinase deficiency (cytosolic PEPCK deficiency) [MIM:261680]. PEPCK deficiency is a metabolic disorder resulting from impaired gluconeogenesis. It is a rare disease with less than 10 cases reported in the literature. Clinical characteristics include hypotonia, hepatomegaly, failure to thrive, lactic acidosis and hypoglycemia. Autoposy reveals fatty infiltration of both the liver and kidneys. The disorder is transmitted as an autosomal recessive trait.
Belongs to the phosphoenolpyruvate carboxykinase [GTP] family.
Acetylation is increased on addition of glucose and appears to regulate the protein stability.